These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7793897)

  • 21. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis.
    Goldfarb J; Stern RC; Reed MD; Yamashita TS; Myers CM; Blumer JL
    Am J Med; 1987 Apr; 82(4A):174-9. PubMed ID: 3555032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of ciprofloxacin in the treatment of patients with cystic fibrosis.
    van den Broek PJ; Bakker W; Mattie H; van Gulpen C
    Pharm Weekbl Sci; 1987 Dec; 9 Suppl():S68-71. PubMed ID: 3438152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What have we learned about early treatment of Pseudomonas aeruginosa infection in infants and children with cystic fibrosis?
    Saiman L; Cohen MB
    Arch Pediatr Adolesc Med; 2011 Sep; 165(9):867-8. PubMed ID: 21893653
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis.
    Smith MJ; White LO; Bowyer H; Willis J; Hodson ME; Batten JC
    Antimicrob Agents Chemother; 1986 Oct; 30(4):614-6. PubMed ID: 3789695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Ciprofloxacin: an alternative oral treatment in respiratory Pseudomonas infection in cystic fibrosis].
    Magni A; Pradal U; Cazzola G; Mastella G
    Pediatr Med Chir; 1990; 12(5):531-4. PubMed ID: 2087426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
    McKnight AJ; Shaw A; Goldsmith CE; Clarke L; Millar BC; McCaughan J; Elborn JS; Reid A; Moore JE
    Br J Biomed Sci; 2005; 62(1):30-2. PubMed ID: 15816210
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety and efficacy of ciprofloxacin in paediatric patients--review.
    Kubin R
    Infection; 1993; 21(6):413-21. PubMed ID: 8132376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term oral ciprofloxacin therapy in a cystic fibrosis patient.
    Willems FT; Haverman FE
    J Antimicrob Chemother; 1988 Jun; 21(6):810-1. PubMed ID: 3410804
    [No Abstract]   [Full Text] [Related]  

  • 29. Ciprofloxacin in cystic fibrosis.
    Smith MJ; Hodson ME; Batten JC
    Lancet; 1986 May; 1(8489):1103. PubMed ID: 2871373
    [No Abstract]   [Full Text] [Related]  

  • 30. Ciprofloxacin: comparative data in cystic fibrosis.
    Rubio TT
    Am J Med; 1987 Apr; 82(4A):185-8. PubMed ID: 3555034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).
    Millar BC; Malnarcic CM; McCaughan J; Moore JE
    Clin Respir J; 2020 Jan; 14(1):64-68. PubMed ID: 31663261
    [No Abstract]   [Full Text] [Related]  

  • 32. Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.
    Vazquez C; Municio M; Corera M; Gaztelurrutia L; Sojo A; Vitoria JC
    Acta Paediatr; 1993 Mar; 82(3):308-9. PubMed ID: 8495091
    [No Abstract]   [Full Text] [Related]  

  • 33. Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.
    Diver JM; Schollaardt T; Rabin HR; Thorson C; Bryan LE
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1538-46. PubMed ID: 1656866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of ciprofloxacin in cystic fibrosis patients.
    Bosso JA
    Am J Med; 1989 Nov; 87(5A):123S-127S. PubMed ID: 2589355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group.
    Richard DA; Nousia-Arvanitakis S; Sollich V; Hampel BJ; Sommerauer B; Schaad UB
    Pediatr Infect Dis J; 1997 Jun; 16(6):572-8. PubMed ID: 9194107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
    Stockmann C; Sherwin CM; Zobell JT; Young DC; Waters CD; Spigarelli MG; Ampofo K
    Pediatr Pulmonol; 2013 Mar; 48(3):211-20. PubMed ID: 22949224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1990 Mar; 34(3):487-8. PubMed ID: 2110438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses.
    Odoul F; Le Guellec C; Giraut C; de Gialluly C; Marchand S; Paintaud G; Saux MC; Rolland JC; Autret-Leca E
    Therapie; 2001; 56(5):519-24. PubMed ID: 11806288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
    Rubio TT; Miles MV; Lettieri JT; Kuhn RJ; Echols RM; Church DA
    Pediatr Infect Dis J; 1997 Jan; 16(1):112-7; discussion 123-6. PubMed ID: 9002120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Photosensitivity rash in a patient being treated with ciprofloxacin.
    Granowitz EV
    J Infect Dis; 1989 Nov; 160(5):910-1. PubMed ID: 2809268
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.